The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal
Abstract
OBJECTIVE: Benzodiazepines, either alone or added to neuroleptics, have been studied extensively as treatments for schizophrenia, but no consensus regarding their efficacy has been reached. The authors review the double-blind trials in the literature and relate the findings to the neurobiology of benzodiazepine actions. METHOD: The clinical review included all double-blind studies through 1989 that could be identified by means of Index Medicus and computer-assisted searches and by the cross-referencing of articles. The findings from the 14 studies of benzodiazepines used alone and the 16 studies of adjunctive therapy are presented separately. RESULTS: The studies reviewed suggest that 1) response is highly variable, and about one-third to one-half of patients improve; 2) benzodiazepines are potentially most useful as adjuncts to neuroleptics in the acute management of psychotic agitation, although actual antipsychotic effects have also been observed in some patients; 3) relatively higher doses of benzodiazepines may be associated with better response; and 4) therapeutic effects, when seen, develop rapidly but diminish after several weeks in some patients. The authors explore the neurobiological bases of benzodiazepine action, which presumably underlie their efficacy in schizophrenia and may help explain the variability of response. CONCLUSIONS: Future research on benzodiazepines in the treatment of schizophrenia should focus on features that predict response, the relation of dopamine or other neurotransmitter systems to therapeutic effects, the schizophrenic symptoms most amenable to benzodiazepine treatment, changes in neuroleptic dose during benzodiazepine augmentation, the role of benzodiazepines in maintenance therapy, and the optimal characteristics of benzodiazepine treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The history of benzodiazepine dependence: A review of animal studies
File, S. E. (1990) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80214-3 · Cited by 101
Marks, J. (1978) · doi:10.1007/978-94-011-6203-6 · Cited by 92
Cited by
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Ferguson, B. R., & Gao, W.-J. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00037 · Cited by 594
Guidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593
Freedman, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035458 · Cited by 587
Lee, K.-H., Williams, L. M., Breakspear, M., & Gordon, E. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00220-5 · Cited by 479
Pincus, H. A., Tanielian, T. L., Marcus, S. C., Olfson, M., Zarin, D. A., Thompson, J., & Zito, J. M. (1998) · JAMA · doi:10.1001/jama.279.7.526 · Cited by 423
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.001 · Cited by 349
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Kane, J. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340109 · Cited by 272
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon
Guidotti, A., Auta, J., Davis, J. M., Dong, E., Grayson, D. R., Veldic, M., Zhang, X., & Costa, E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2212-8 · Cited by 262
Pharmacological Management of Acute Agitation
Battaglia, J. (2005) · Drugs · doi:10.2165/00003495-200565090-00003 · Cited by 254
Lewis, D., Volk, D., & Hashimoto, T. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1673-x · Cited by 253
“However, the use of GABA-related treatments for schizophrenia has not been a major focus of research in recent years, principally because a large series of studies in which benzodiazepines were used to treat psychosis revealed that the high dosages required produced unacceptable side effects such as excessive sedation…”
BackgroundDeidda, G., Bozarth, I. F., & Cancedda, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00119 · Cited by 192
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153
Menzies, L., Ooi, C., Kamath, S., Suckling, J., McKenna, P., Fletcher, P., Bullmore, E., & Stephenson, C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.156 · Cited by 120
The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis
Taylor, S. F., Grove, T. B., Ellingrod, V. L., & Tso, I. F. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz046 · Cited by 67
Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1991-06-01
- Volume
- 148
- Issue
- 6
- Pages
- 714-726
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W64322893
- Cited by
- 221
- References
- 2
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.